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Available online 12 February 2013Abstract Human adipose derived stem cells (hASCs) can be easily isolated and their plasticity has been well characterized.
Several TGF-β superfamily ligands can direct hASCs towards chondrocytes. However, these ligands are difficult to purify and
expensive. We have developed a library of Activin/BMP2 chimeric ligands (AB2 ligands) by systematically mixing their sequence
segments and have tested their chondrogenic potential in hASCs. Cells cultured in monolayer or in a pellet culture system were
incubated with a chemically defined medium supplemented with the chimeric ligands for 4 or 6 weeks and showed higher
expression levels of type II collagen, aggrecan, and Sox9 mRNAs when compared with control and non-treated cells. Moreover,
toluidine blue, alcian blue, and Masson's trichrome staining was markedly increased in treated cells, both in cell pellet and
monolayer assays. In addition, immunohistochemical staining for detection of type I collagen, type II collagen, and Sox 9
demonstrated the acquisition of a chondrogenic phenotype in both culture systems. We present here an inexpensive and robust
protocol for differentiation of hASCs towards chondrocytes in a reproducible and highly efficient manner. The AB2 ligands
employed are easily produced and have properties that may become useful in cell therapy.
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http://dx.doi.org/10.1016/j.scr.2013.02.002Degenerative diseases associated with age represent a major
health challenge in developed countries. The intrinsic prop-
erties of cartilage tissue, its avascular nature, and deficient
self-repair capacity imply that cartilage degeneration or
associated injures may become a chronic problem. To date
no effective solution has been found. Moreover, cartilage
degeneration causes not only joint pain and dysfunction, but
also increases the percentage of people with limited mobility.
465TGF-β ligands direct hASC to chondrogenesisCartilage is a connective tissue formed by only one cell
type, the chondrocyte, trapped in the extracellular matrix
composed mainly of collagen fibers, aggrecan (a large
aggregating proteoglycan) and water. In fact, many efforts
are currently being made to create cartilage in laboratories
by combining novel biomaterials, growth factors and cells
(Moreira-Teixeira et al., 2011).
Clinical treatment for articular cartilage injury includes
autologous cell injections of primary chondrocytes expanded
in vitro. However, the dedifferentiation of the autologous
chondrocytes in culture and the small number of cells that
can be obtained limit their clinical applications only to small
injuries (Schuurman et al., 2012). Alternative cell sources
for cartilage tissue engineering are mainly embryonic stem
cells and adult stem cells. Mesenchymal stem cells derived
from bone-marrow (MSCs) and adipose tissue (ASCs) have
shown significant chondrogenic potential (Diekman et al.,
2010; Estes et al., 2010; Pittenger et al., 1999). Importantly,
ASCs can be easily harvested, expanded in vitro and are
relatively abundant in comparison with MSC. Therefore,
ASCs could be an ideal cell type for generating a large
number of functional chondrocytes.
The transforming growth factor-β (TGF-β) superfamily is
comprised of almost forty ligands responsible for numerous
cellular processes including early embryonic development,
tissue patterning and homeostasis, bone formation, wound
healing and fibrosis (Attisano et al., 1993; Hogan, 1996a,
1996b). These proteins signal through the simultaneous
interaction with one of the 7 type I and one of the 5 type II
TGF-β receptor (TGFR-β) kinases. The signaling requires
the hetero-dimerization and subsequent activation of both
types I and II receptors through the binding of their TGF-β
ligands (Derynck and Feng, 1997). Interestingly, different
TGF-β ligands, such as Activin (Jiang et al., 1993) as well as
several isoforms of bone morphogenetic protein (BMPs)
(Denker et al., 1999; Estes et al., 2010; Kramer et al., 2000;
Majumdar et al., 2001), TGF-β1 (Awad et al., 2003; Erickson et
al., 2002) or TGF-β3 (Hennig et al., 2007), have been shown to
promote chondrogenesis. Since Activin A exhibits high affinity
for type II receptors and signals through SMAD2/3 transcription
factors, while BMP2 possesses higher affinity for type I receptors
and signals through SMAD1/5/8 transcription factors, we
investigated whether AB2 chimeras created by mixing Activin
and BMP2 sequences (Allendorph et al., 2011) would be useful
in promoting chondrogenesis. In short, BMP2 and Activin A
sequences have been divided into 6 structural segments
and these segments have been mixed to create the AB2
library of chimeras with novel functional properties. A
systematic swapping strategy of the segments termed
Random Assembly of Segmental Chimera and Heteromers
(RASCH) was described in detail in Allendorph et al. (2011).
The chimeras are fully defined by the code (BXXXXX), where
X=A (Activin A) or B (BMP2) depending on which segment is
in position X.
Although it has been reported that the use of defined
media with specific cytokines induces chondrogenic dif-
ferentiation in ASCs, the degree of maturation, efficiency
and duration of the process still need to be improved. In
this study, we have tested the chondrogenic potential of a
battery of AB2 chimeras produced in our laboratory and
concluded that AB235 could efficiently (i) upregulate the
expression of chondrogenic-related genes, (ii) induce collagensand proteoglycans synthesis and (iii) increase chondrogenic cell
pellet size using human ASCs.
In conclusion, we present here an inexpensive, robust
protocol for differentiation of a large number of human ASCs
towards chondrocytes in a reproducible and efficient manner.
The scalable number of chondrocytes obtained by the induction
with this AB2 ligandmay have novel and important implications
for cell replacement therapies in cartilage repair clinical
protocols.
Material and methods
Generation of TGF-β Chimeras
The AB2 library was generated as previously described
(Allendorph et al., 2011). Briefly, the mature domains of
both human BMP2 and human Activin A were divided into 6
segments and primers were designed for each segment. An
overlapping PCR strategy was used to mix the various
segments together to generate full-length PCR fragments of
each chimera. The AB235 chimera was created from AB208
(BAAAAA) by mutating IIKKDIQN from segment 6 to VVLKNYQD
using a Quickchange kit. We introduced this mutation to make
AB208 Noggin sensitive. The mutation was designed based on
our BMP7/Noggin complex (Groppe et al., 2002). The desired
protein sequences were confirmed by DNA sequencing.
Proteins were expressed in E. coli as inclusion bodies and
purified as previously described (Allendorph et al., 2011).
ASCs cell culture
Human mesenchymal stem cells were derived from the
adipose tissue from the subcutaneous abdomen of a
37-year-old Caucasian female (lot number 9061601.12,
PromoCell, Heidelberg, Germany). Cells were cultured in
“growing medium”: high glucose Dulbecco's modified
Eagle's medium (DMEM, Invitrogen) with 10% fetal bovine
serum and 1% penicillin/streptomycin (Invitrogen).
Induction of monolayer expanded cells
towards chondrocytes
hASCs were induced to chondrogenic phenotype as previ-
ously described (Estes et al., 2010) with slight variation.
Briefly, cells were seeded at 30–40% confluence in a 12 or
24-well plate. Non-treated cells or control cells were grown
in “incomplete chondrogenic medium” (CTL): DMEM–high
glucose (Invitrogen) supplemented with 10% fetal bovine
serum and 1% ITS+Premix (Collaborative Biomedical–Becton
Dickinson, Bedford, MA), in the presence of 1% penicillin–
streptomycin (Invitrogen). In addition, 50 μg/μL of l-ascorbic
acid 2-phosphate (Sigma-Aldrich) was added fresh during each
media exchange. To direct chondrogenic differentiation,
cells were cultured in “chondrogenic medium”: incomplete
chondrogenic medium containing 10 ng/ml of the chimeric
ligand. Media was changed every other day. Cells were
cultured in chondrogenic media for 2, 4 and 6 weeks
depending on the experiment. Complete chondrogenic
medium with 10 ng/ml of BMP2, known to be capable of
chondrogenesis, was used as positive control. In addition,
466 M. Peran et al.we compared the chondrogenesis potential of AB2 chimera
ligands and TGF beta3 at two different concentrations:
10 ng/ml and 50 ng/ml.
Chondrogenic differentiation in cell pellet culture
Two different methods were used to induce the formation of a
cell pellet culture. In the first method, a suspension of 250,000
cells, in either growing media, incomplete chondrogenic
medium or chondrogenic medium, was added to 15-ml conical
tubes and centrifuged at 300 g at 21 °C for 5 min to form a
pellet at the bottom of each tube. The pellets appeared as a
round-shaped mass at the bottom of the tube. In the second
method, cells were grown in 12-well plates in chondrogenic
medium and after confluency, the monolayer spontaneously
detached from the plastic and took the form of a crumpled
paper ball. Control cells grown in incomplete chondrogenic
medium did not detach spontaneously from the plastic and,
therefore, the monolayer was manually separated using a
sterile tip. The emerging pellets were carefully transferred to
15-ml conical tubes. This was done after two weeks from
seeding cells in the 12-well plates. Tubes were incubated with
loosened tops at 37 °C and 5% CO2. Medium was exchanged
every other day for the duration of the experiment, and tubes
were gently shaken to avoid the adherence of the pellet to the
plastic walls.
RNA isolation and real time-PCR analysis
Real-time PCR was performed to study the differentiation
profile of the hASCs in order to analyse the expression of key
cartilage markers. Total cellular RNA was isolated using Trizol
Reagent (Invitrogen) according to the manufacturer's recom-
mendations. 2 μg of DNAse1 (Invitrogen) treated total RNA
was used for cDNA synthesis using the SuperScript II Reverse
Transcriptase kit for RT-PCR (Invitrogen). Real-time PCR was
performed using the SYBR-Green PCR Master mix (Applied
Biosystems). Sequences of primers were 5′GGACTCATGAC
CACAGTCCATGCC3′ and 5′TCAGGGATGACCTTGCCCACAG3′ for
GAPDH; 5′AGGATGGCTTCCACCAGTGC3′ and 5′TGCGTAAAAG
ACCTCACCCTCC3′ for aggrecan (ACN); 5′GAGACAGCATGAC
GCCGAG3′ and 5′ GCGGATGCTCTCAATCTGGT3′ for type II
collagen (COL2A1); 5′ATGGATGAGGAAACTGGCAACT3′ and 5′
GCCATCGACAAGAACAGTGTAAGT3′ for type I collagen
(COL1A1); 5′ ACTCCGAGACGTGGACATC3′ and 5′TGTAGG
TGACCTGGCCGTG3′ for Sox9 (SOX9); 5′AGAACCTCGAAG
ACATCGGC3′ and 5′GGCTGAGGGTTAAAGGCAGTG3′ for Runx1.
The gene expression levels were normalized to corresponding
GAPDH values and are shown as fold change relative to the
value of the control sample. All the samples were done in
triplicate for each gene.
Cell monolayer and cell pellet processing
For histological and immunocytochemistry analyses, monolay-
er expanded cells and culture pellets were processed as
follow. Culture pellets were fixed with 4% paraformaldehyde
for 20 min at room temperature and embedded in 2.3 M
sucrose for 1 h. Cell pellets were embedded in Tissue Freezing
Medium, Blue (Electron Microscopy Sciences) and frozen on
dry ice. Sections of 2–6 μm in thickness were cut with amicrotome and placed in the centre of a coated slide. Sections
were washed with PBS in a humid chamber, until the excess
sucrose washed away. Monolayer expanded cells were washed
thrice in PBS and fixed with 4% paraformaldehyde for 20 min
at room temperature (RT).
Histochemical determinations
Toluidine blue staining: 0.1 g of toluidine blue (Sigma) was
dissolved in 100 ml of dH2O. Fixed cells and pellet sections
were stained in toluidine blue solution for 1–5 min at RT,
and rinsed with dH2O until the excess stain washed away.
Alcian Blue Staining: 1 g of Alcian blue (Sigma) was diluted in
3% acetic acid solution, and pH was adjusted to 2.5 with
acetic acid. Fixed cells and pellet sections were stained in
Alcian blue solution for 20 min at RT, and washed with dH2O
until the dye was gone. Masson's Trichrome Staining: we used
Masson's trichrome kit (Sigma) for the detection of total
collagen content. The collagen fibers will be stained blue,
the nuclei will be stained dark brown/purple and the
cytoplasm is stained red/pink.
Fluorescence microscopy
Briefly, after fixation, monolayer expanded cells and pellet
sections were blocked and permeabilized for 1 h at 37 ° C
with 5% BSA/5% appropriate serum/1X PBS with 0.1% Triton
X100. Subsequently, cells and sections were incubated with
the indicated primary antibody overnight at 4 °C. Monolayer
expanded cells and pellet sections were next washed thrice
with 1X PBS and incubated for 2 h at 37 °C with the
respective secondary antibodies and washed thrice with 1X
PBS. DAPI (0.5 μg/ml in PBS) was used to visualize the
nuclei. Cells were mounted with aqueous mounting media
before analysis.
Primary antibodies used were anti-type I collagen antibody
(rabbit polyclonal antibody (ab292), Abcam, Cambridge,
MA), anti-type II collagen antibody (mouse monoclonal
antibody (ab3092), Abcam, Cambridge, MA), type X colla-
gen (Neomarkers, Fremont, CA) or anti-Sox9 antibody
(rabbit polyclonal antibody (AB5535), Chemicon). Second-
ary antibodies were Alexa Fluor 568 or 488 (Neomarkers).
The pictures were taken with either a Leica TCS SP2 AOBS
confocal or a Nikon E-800 microscope.
Results
Upregulated expression of chondrogenic genes after
induction with chimeric ligands in ASCs
To select chimeric ligands with higher ability to induce
chondrogenesis, we performed real time PCR analyses of
cells grown in monolayer for two weeks in chondrogenic
induction media. We observed enhanced gene expression of
the principal cartilage extracellular matrix components, type
II collagen (Col II) and aggrecan in all of the chimeras tested
when compared to control cells, suggesting the enormous
potential of these constructs (Fig. 1). Among all the chimeras,
AB235 showed the most prominent chondrogenic effect since
it markedly upregulated Col II mRNA to an average of 13-fold
467TGF-β ligands direct hASC to chondrogenesiscompared with the control. This chimera also increased
aggrecan mRNA expression 14-fold and Sox 9 mRNA expression
9-fold. In addition, AB204 and AB215 also showed increased
expression of these chondrogenic makers (Fig. 1).
Based on the real time PCR results we concluded that the
chimeric ligands that induced major increase in chondrogenic
markers expression were, in order from most to least, AB235,
AB204, and AB215. Therefore these ligands were chosen to
perform further experiments to fully assess their chondrogenic
induction capacity.Formation of extracellular proteoglycan matrix
The degree of maturation after chondrogenic differentiation
was further assessed by toluidine and alcian blue staining of
monolayer cultured cells. Accumulation of glycosaminogly-
cans in the extracellular environment indicates the forma-
tion of a cartilage matrix, and can be positively stained by
toluidine and alcian blue. We observed a noticeable increase
in the intensity of alcian blue staining in cells treated with
AB235 for two weeks when compared with control cells (CTL)igure 1 Chondrogenic differentiation of hASCs after treatment with several AB2 ligands. Real-time PCR analysis of selected
hondrogenic markers after the cells were cultured for 14 days in complete chondrogenic medium containing the different chimeric
gands. Gene expression is shown as fold change relative to cells cultured in incomplete chondrogenic medium (CTL). GAPDH
xpression was used for normalization. Data are shown as average±95%CI (n=3) from at least 2 independent experiments.F
c
li
eor cells treated with different chimeras, such as AB204 and
AB215. Furthermore, the intensity of the alcian blue staining
was comparable between AB235- and BMP2-treated cells
(positive control cells) (Fig. 2A–K). Fig. 2G–K shows, in more
detail, the striated distribution of the cartilage extracellular
matrix and a strong blue staining for AB325- and BMP2-treated
cells is apparent (Fig. 2G and I, respectively). We also tested
toluidine blue staining in cells treated with two different
concentrations of AB235 (Fig. 2L–M) and TGF-β3 (Fig. 2N–O).
We observed that AB235- and TGF-β3-treated cells showed a
similar dose-dependent increase in the intensity of toluidine
blue staining. However, the intensity of staining in control
cells was low (Fig. 2P). These results revealed the presence of
acidic proteoglycans characteristic of the cartilaginous matrix
in cells treated with chimeric ligands.Formation of cartilage-like tissue
We used a cell pellet culture model which requires a high cell
density to create compact cell-cell contacts mimicking the
cellular condensation process occurring in normal limb
468 M. Peran et al.development (Johnstone et al., 1998). As far as we know, the
method to induce pellet formation as a detached monolayer
with “crumpled paper ball” form has not been used before to
induce chondrogenesis (described in mat. and met. section).
This method was development based in the concept of
prechondrogenic mesenchymal condensations. In fact, mes-
enchymal cells seem to acquire a cohesive cell behavior,
termed compaction, which is a critical cellular event required
for cartilage formation (Barna and Niswander, 2007). Fig. 3F–J
shows that the cell pellets achieved a cartilage-like appear-
ance with a white shiny look. In addition, we clearly observed
that both pellets prepared with the traditional centrifugation
method (Fig. 3A–E) and with the new methodology (Fig. 3F–J)
differed in size depending on the ligands included in the
medium. In both methods, we observed a significant increase in
cell pellet size when AB235 (Fig. 3B and G) or BMP2 (Fig. 3D and
I) was added to the medium in comparison with cell pellets
grown in incomplete chondrogenicmediumwith no ligands (Fig.
3E and J), or with AB215 (Fig. 3A and F), or AB204 (Fig. 3C and
H). This increment in size was slightly larger when the pellets
were obtained by previous monolayer culture. Furthermore, we
were not able to form a pellet when cells were fed only with
growing medium (data not shown). We further investigated the
formation of cartilage-like tissue using toluidine blue staining in
cell pellet sections. Active matrix production was detected in
AB2 chimeras- and BMP2-supplemented pellet cultures (Fig.Figure 2 Photographs of monolayer expanded cells cultured for 14
different increment of proteoglycans deposition (revealed by alcian
(A). Higher resolution images of the same cells as in A are sho
dose-dependent as demonstrated with the accumulation of toluidi
medium with 10 ng/ml (L and N) or 50 ng/ml (M and O) of: AB235 (
Scale bars B–F and L–P: 6 mm; Original magnification for G–K was 13K–N). Note that the control cells (Fig. 3O) did not display
tissue-like organization and rather present the appearance
of a cell aggregation with no clear organization. A
non-uniform distribution pattern of toluidine blue staining
in treated cells is shown in more detail in Fig. 3P–S. These
dense regions of a characteristic positive metachromatic
staining are evidence of glycosaminoglycans synthesis.
Furthermore, the Masson's trichrome staining of pellet
cultures grown with AB235 supplementation (Fig. 4A–C)
revealed the typical appearance of cartilage tissue with
blue staining for collagen fibber deposits that form a dense
matrix containing the differentiated chondrocytes, stained
in dark brown, within lacunae (Fig. 4C). These results
reinforce the observed high potential of AB235 in promoting
chondrogenesis.
To quantify the chondrogenic potential of the hASC
cultured in a pellet system, we performed real-time PCR
analysis of genes related to cartilage differentiation 6 weeks
after treatment with chimeric ligands (Fig. 4D). Upon AB235
treatment, we observed increased expression of a number of
chondrogenic markers including type II collagen (455-fold),
Sox9 (9-fold) and Aggrecan (67-fold) as compared with the
control, whereas the expression of the fibrous tissue marker
type I collagen (Col I) decreased. These results suggested
that ASCs were successfully induced towards an articular
chondrogenic lineage by the chimeric ligand AB235.days with 10 ng/ml of different AB2 ligands and BMP2, showing a
blue labelling) depending on the ligands added to the medium
wn in B–K. L–O: Chondrogenic induction of the ligands was
ne blue positive material. Cells were cultured in chondrogenic
L–M) and TGF beta3 (N–O) and compared with control cells (P).
0×.
Figure 3 Representative image of pellets (formed by centrifugation) in 15-ml conical tubes 6 weeks after culture in chondrogenicmedium
containing 10 ng/ml of different AB2 ligands (A-C); or BMP2 as positive control (D). Cells grown in incomplete chondrogenic medium were
used as negative control (E). hASCs cultured in a pellet system (formed by detached monolayer) on day 42 treated with AB2 ligands (F–H);
BMP2 (I) or non-treated cells (J). Toluidine blue stain of sections of the same pellets (K–T). Scale bars A–E: 3 mm; F–O: 1 mm; P–T: 350 μm.
469TGF-β ligands direct hASC to chondrogenesisChondrogenic protein expression
Next, to further evaluate the chondrogenic potential of the
chimeric ligands, we performed inmunocytochemistry assays
on cells grown in monolayer for 4 weeks (Fig. 5) or a pellet
system differentiated after 6 weeks (Fig. 6). Monolayer
cultured cells treated with AB204 (Fig. 5A–C) and AB235
(Fig. 5G–I) clearly demonstrated an increase in the expression
of type II collagen which develops a dense filamentous matrix
network deposited over the cells (Fig. 5B–C, H–I respective-
ly). When cells were treated with AB208 (Fig. 5D–F) Col II
expression was slightly lower, showing a similar pattern as
BMP2 treated cells (Fig. 5J–L).
Furthermore, immunostaining of Col II and Col I in
AB235-treated cells cultured in a pellet system (Fig. 6) also
showed a substantial number of Col II positive cells (Fig. 6E,
F, H and I), which formed a dense filamentous network of
collagen II connecting the cells. Interestingly, we did not
detect co-localization of collagen I (Fig. 6D and G) and II as
Col I-positive cells were located surrounding Col II-positive
cells, which strongly resemble a stratified structure in the
tissue (Fig. 6F and I). Control cells (Fig. 6A–C) did not show
tissue-like appearance or a strong, positive label of the
chondrocyte markers tested.
In addition, expression of the chondrogenic transcription
factor Sox9 was highly enriched in AB253-treated cells
(Fig. 6L) when compared with control cells (Fig. 6J) in pellet
sections. Sox9 protein was found localized in both nucleus andcytoplasm. In agreement with our results, others authors have
also found Sox9 protein localization within the cytoplasm of
chondrocytes (Aigner et al., 2003).
Finally, we stained the pellet section with type X collagen,
a marker of hypertrophic chondrocytes committed to the
osteogenic lineage, and did not observe significant positive
staining in pellet section cultured with AB235 (Fig. 7H–I),
while BMP2 treated cells showed a slight but significant
expression of Col X (Fig. 7E–F). Altogether, these data
suggested that ASCs acquired a mature chondrocyte-like
phenotype induced by the activity of the chimeric ligand
AB235.Time points of chondrogenesis induction
To analyze the timing of the chondrogenic differentiation
process during the exposition of the hASC to chimeric ligands,
we collected samples at different time points (2, 4 and
6 weeks) and studied the expression of some early (Sox9 and
Runx1) and late (Col II and I) markers of the chondrogenic
pathway. Gene expression at the different time points was
compared to cells that had been maintained in the same
conditions as the treated cells, and collected at the same time
points, but grown in media without any chimeric ligand or
BMP2.
Fig. 8A shows that Col II gene expression increased over the
period of differentiation and reached a 39-fold increment
Figure 4 Masson's Trichrome staining of AB235 treated cells in pellet cultures (A–C) showed marked collagen fibbers with blue
label. A high magnification view of (A) is shown in (B). A stained section from a different pellet is shown in (C), where the formation of
collagen matrix lacunae can be seen. Expression of chondrogenic markers in a pellet culture (D). Pellets were cultured with AB235 or
BMP2 for 6 weeks. RT–PCR analysis of chondrogenic gene markers (Col II, Col I, Sox9 and Aggrecan) normalized to GAPDH and shown
as relative gene expression to cells cultured in incomplete chondrogenic medium. Data are shown as average±95%CI (n=3) from at
least 2 independent experiments. Original magnification: 5× for A; 10× for B and 40× for C.
470 M. Peran et al.6 weeks after the treatment with AB253. Col I expression was
significantly increased in both treatment groups (AB235 and
BMP2) as compared to control cells (Fig. 8B) reaching maximum
expression after four weeks of treatment. Moreover, after
14 days of treatment with chondrogenic mediumwe observed a
modest and transient enhancement of the Runx1 mRNA level,
which was more evident in AB235 treated cells. The Runx1
expression level decreased in later time-points for all treat-
ments (Fig. 8C). Chondrocyte differentiation is initiated by
expression of the transcription factor Sox9. After 2 weeks of
culture in media supplemented with BMP2, Sox9 expression
enhanced 21-fold but dropped to 9-fold after 4 weeks. The
addition of AB235 to the media also increased Sox9 gene
expression 9-fold after four weeks of culture. After 6 weeks of
culture the expression of this transcription factor decreased for
both treatments (Fig. 8D).Discussion
Differentiated chondrocytes are capable of proliferating and
secreting numerous growth factors and cytokines to form the
extracellular matrix in mature cartilage (Fischer et al.,
2010; Keller et al., 2011). During chondrogenesis, theseevents are precisely regulated by different growth factors
and soluble factors released from cartilage elements as well
as from the perichondrium (Hwang et al., 2011). Previous
studies have shown that chondrocyte-derived factors may
influence the fate of mesenchymal cells via paracrine,
juxtacrine or gap-junction signalling pathways (Cheng et al.,
2009; Gelse et al., 2009), suggesting that these factors can
stimulate the formation of extracellular matrix in precursor
cells and could be essential for regenerative medicine
applications (Hwang et al., 2008). These factors are, however,
difficult to produce in sufficient quantity. The development of
new molecules with increased activity in driving MSCs and
ASCs towards chondrogenic differentiation is, therefore, a
priority in regenerative medicine and pharmaceutics.
On the other hand, there is accumulating evidence that
co-culture multipotent stem cells, such as ASC and MSC, with
patient derived chondrocytes can be used to induce chondro-
genesis without the need for exogenous cytokines and growth
factors (Wu et al., 2012a; Leijten et al., 2012). In addition, it
has been shown that trophic factors secreted by the MSCs/ASCs
induce cartilage formation by stimulating chondrocyte prolifer-
ation and matrix deposition by chondrocytes, rather than MSCs
actively undergoing chondrogenic differentiation (Wu et al.,
2011;, 2012b). Although these findings are interesting and could
Figure 5 Indirect immunofluorescence of monolayer cultured hASCs 4 weeks after treatment with AB204 (A–C), AB208 (D–F),
AB235 (G–I) and BMP2 (J–L) or grown in incomplete chondrogenic medium (M–O). Expression of cartilage-specific collagen II protein
with intense green staining can be seen in treated cells, showing the characteristic collagen fibers framework of cartilage. 20×
original magnification for: A, D, G, J and M; 40× original magnification for: B, C, E, F, H, I, K, L, N and O.
471TGF-β ligands direct hASC to chondrogenesisrepresent a suitable alternative for cartilage repair, we present
here a different approach that is not based on the use of
autologous chondrocytes. In this respect, we previously
established a procedure that allowed us to generate a large
quantity of BMP2/BMP6 heterodimer (BMP-2/6) by a chemical
refolding method, and demonstrated that BMP-2/6 is a better
inducer of differentiation of human embryonic stem cells
(hESCs) than its homodimeric counterparts (Valera et al.,
2010). In addition, using a segment-swapping RASCH strategy
with BMP2 and Activin-A sequences, we have demonstrated that
one such AB2 library chimera, AB208, exhibits the refolding
characteristics of BMP2 while possessing Activin-like signaling
attributes (Allendorph et al., 2011). Since BMP2 has been
proven to enhance gene expression of cartilage-specific genes
and proteoglycans in hMSCs (Sekiya et al., 2001, 2005), these
chimeras can be good candidates for stem cell differentiation/
guidance.
In the present study we analyzed the chondrogenic potential
of A/B2 chimera ligands on hASC. Firstly, we assayed their
ability to up-regulate the expression of genes involved in
chondrogenesis. AB2-ligands increased collagen II, aggrecan or
Sox9 expression, which demonstrated a potential in inducing
chondrogenic differentiation (Li et al., 2011; Yoo et al., 1998).
The level of induction of chondrogenic genes was highly
dependent on the chimeric ligands used, with AB235 showing
the strongest chondrogenic potential both in monolayer and
pellet culture systems. Time point evaluations confirmed that
chondrogenic differentiation induced by AB235 exhibited a
similar pattern to that of the cartilage maturation process
with an initial increase of Col I and Sox9 and a decline at later
times, a time-dependent increase in expression of Col II, and a
marked decrease of Runx1 levels. Sox9 acts in early stages
of chondrocyte differentiation, which directly inducestype II collagen (Lefebvre et al., 1997) and is expressed in
mesenchymal condensations (Lefebvre and de Crombrugghe,
1998). Decreased Col I gene expression suggested that AB2
ligands induced articular chondrocyte differentiation, as type-I
collagen is either present in very small amounts or absent in
hyaline cartilage, but abundant in fibrocartilage (Eyre and
Muir, 1977; Roberts et al., 2009). Runx1 is a transcription
factor highly expressed during early chondrogenesis and is
downregulated in late stages of chondrocyte differentiation.
Moreover, it has been demonstrated that Runx1 is capable of
accelerating induction of MSC differentiation towards chon-
drogenesis by increasing the expression of early chondrocyte
maturation markers (Wang et al., 2005). Thus, our results
indicate that AB235 is superior in inducing chondrogenesis
from early to late stages of maturation.
Members of the TGF-β superfamily, TGF-β1 or TGF-β3,
have been shown to induce chondrogenic differentiation
(Johnstone et al., 1998; Mackay et al., 1998; Tanaka et al.,
2004). In this respect, Lorda-Diez et al. (2011) have performed
an elegant in vivo study to identify the temporal hierarchy of
the genes which orchestrate chondrogenesis. The experimen-
tal model consisted in the induction by TGF-β of an ectopic
digit in the developing embryo and concluded with the
postulation of three different periods in the transition from
mesoderm towards cartilage: i) the pre-condensation stage,
characterizedmainly by upregulation of Sox9, ii) condensation
stage, with the activation, among others, of Activin bA and
BMP receptor genes; and iii) pre-cartilage period, character-
ized by the intensification of the expression of Sox9 which
precedes the upregulation of Aggrecan and type II Collagen
genes.
The TGF-β family is divided into two subfamilies, the
TGF-β/Activin/Nodal and the BMP/GDF, which members play
Figure 6 AB2 ligands-treated cell pellets formed a “cartilage like” tissue organization. hASC cell pellet cultures were grown in
medium supplemented with AB235 (D–I) and incomplete chondrogenic medium (A–C) for 6 weeks, fixed and inmunostained with Col I
and Col II antibodies. Protein expression was detected in red for Col I and green for Col II. Cell nuclei were labelled with DAPI (blue
channel). Tissue organization in stratified layers showed Col I stained cells enveloping Col II producing cells. Expression of
chondrogenic transcription factor Sox9 in culture pellet sections. Immunofluorescence of Sox9 was analysed after 6 weeks of
treatment with AB235 (K–L) and control cells (J). Proteins were indirectly labelled with secondary antibodies (green channel) and cell
nuclei labelled with DAPI (blue channel). (K) shows nuclear staining of the same field as (L). In (L), note nuclear localization of Sox9
(arrows). Original magnification 20x for: A–F and J; 40× for: G, H, I, K; and L.
472 M. Peran et al.a key role in regulating development, differentiation, and
tissue repair and display complementary effects (Chng et al.,
2011). TGF-β signaling via a heteromeric cell surface serine/theorine kinase receptor complex consisting of a dimeric
ligand and a pair of both type I and type II receptors (Attisano
and Wrana, 2002; Heldin et al., 1997). The type II receptors
Figure 7 Hypertrophic marker type X collagen expression in pellet section grown in incomplete chondrogenic medium (A–C) and in
grown in medium supplemented with BMP2 (D–F) or AB235 (G–I). Col X was labelled in red and cell nuclei were visualized by DAPI
staining (blue). Original magnification 20× for: A, B, C, G, H and I; 40× for: D, E and F.
473TGF-β ligands direct hASC to chondrogenesiskinases are activators of the type I receptor known as activin
receptor-like kinases (ALKs). TGF-β ligands assembles a
receptor complex of one of five type II TGF-β receptor
kinases and subsequent cross-phosphorylation of one of seven
type I receptors which triggers phosphorylation of the cytoplas-
mic receptor-regulated SMAD molecules. Indeed we show here
that the major difference between AB235 and BMP2
treatment was visible in the upregulation of Sox9 expres-
sion. This observation could indicate that Sox9 upregulation
is linked to both SMAD2/3 and SMAD 1/5/8 activation,
whereas the increase in Col II is mainly regulated by BMP2
presumably through SMAD 1/5/8. In fact, it has been
recently shown that Smad 4 silencing (blocks both SMAD
1/5/8 and SMAD 2/3 intracellular signaling) targeted to limb
mesoderm causes a dramatic inhibition of chondrogenesis
of digit progenitors (Bénazet et al., 2012). Moreover, both
Sox9 and Col II proteins were synthesized in great amount
by the hASCs supplemented with AB235 for 6 weeks. It has
been previously demonstrated that Sox9 in concert with
L-Sox5 and Sox6, regulates cartilage formation andmaintains the chondrocyte phenotype in the mature cartilage
by activating expression of several cartilage-specific genes,
including Col2a1, Col9a1 and Col11a1, Acan and Comp (Han
and Lefebvre, 2008).
BMPs have a synergistic effect with TGF-β on promoting
MSCs into hyaline-like cartilage tissue (Toh et al., 2005) and
also signal through activin type II receptors (ActrII) or ALKs.
In addition, signaling through the BMP receptors is required
for the maintenance of the articular cartilage in post-natal
organisms (Rountree et al., 2004).
Finally, we showed here that while AB235-treated cells
almost did not express Col X, this hypertrophic marker slightly
increased after BMP2 treatment. In fact, BMP2 also mediates
the replacement of chondrogenesis by endochondral ossifica-
tion comprising chondrocyte maturation, hypertrophy, and
transition from type II to type X collagen with subsequent
chondrocyte apoptosis. Thus, chondrogenic cultures induced by
BMP2 display high expression of genes associated with chondro-
cyte hypertrophy (Steinert et al., 2009). In addition, in vivo
studies have demonstrated that BMP2 expressing MSCs resulted
Figure 8 Gene expression analysis of hASC at different
time-points during the differentiation protocol. hASC were
cultured in AB235 and BMP2 enriched media for 2, 4, and
6 weeks. Total mRNA was obtained at each time-point, and
transcript levels of Col II, Col I, Runx1 and Sox9 were analyzed by
real-time PCR, normalized to GAPDH and shown as relative gene
expression compared to cells cultured in incomplete chondrogenic
medium. Data are shown as the average±95%CI (n=3).
474 M. Peran et al.in tissue hypertrophy and the formation of osteophytes, when
transplanted orthotopically to osteochondral defects (Gelse et
al., 2003).
The results presented here confirm that AB235 enhanced
hASCs chondrogenic differentiation in comparison with indi-
vidual treatment with BMP2, suggesting that this chimeric
ligand could signal through both type I and type II receptors
more efficiently, thereby increasing cartilage maturation. In
fact, both BMP2 and Activin can bind ActrII (activin with very
high affinity and BMP with lower affinity) (Chen et al., 2002).
In addition, differences in the level of endogenously secreted
growth factors and/or in the expression of their specific
receptors might modulate the resulting phenotype of the
target cell and could be responsible for the success of
chondrogenic differentiation in MSC (Hennig et al., 2007).
A main strategy of regenerative medicine is the construc-
tion of a biocompatible scaffold that, in combination with
living cells and/or bioactive molecules, replaces, regener-
ates or repairs damaged cells or tissue (Perán et al., 2012;
López-Ruiz et al., 2012). Growth factors are commonly used
to enhance the scaffold's bioactivity and facilitate tissue
growth and regeneration. The rationale of incorporatinggrowth factors within a construct, is to allow the surrounding
cells to attach to the scaffold via surface receptor binding,
activate their signaling pathways and dictate them to
migrate, proliferate, differentiate and synthesize proteins
during tissue regeneration (Lutolf and Hubbell, 2005). Thus
further studies to evaluate the effect of the incorporation of
AB235 to bio-compatible scaffolds could have important
clinical application in the near future.
Conclusions
Here we present an optimized, reproducible and inexpensive
protocol to direct the differentiation of adipose stem cells
into the chondrogenic lineage. Our chimeric ligand AB235
has proven to be highly efficient to induce chondrogenesis
from hASC. This novel differentiation culture system may be
extended to other cell and tissue types and thus could have
broad clinical applications.
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